Dr. Hurtado-Lorenzo is responsible for planning and oversight the Foundation’s translational research portfolio that is advancing solutions for patients based on research in the fields of Precision Medicine, Genetics, Microbiome, Biomarkers, and Biosensors. He also heads the Foundation’s venture philanthropy program, IBD Ventures, to advance new product development for IBD in for-profit and non-profit organizations. He is a translational scientist leader with previous success directing multidisciplinary teams in the biotech and pharmaceutical industry (Pfizer, Wyeth, Proteostasis Therapeutics), resulting in the development of candidate drugs currently in clinical trials. He obtained his Ph.D. in Molecular Medicine from the University of Manchester UK, where he pioneered work in gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research on autophagy and other protein degradation pathways. His research has been published in books and high impact journals.